Company: TWi Biotechnology, Inc
Job title: Senior Director
Dr. Yiumo Chan is currently the Department Head of Medical Research in TWi Biotechnology, a clinical stage biopharmaceutical company specializing in the development of repositioned drugs for immunological skin and rare diseases associated with chronic inflammation. During his drug development career, Dr. Chan demonstrated a successful record in advancing preclinical programs to clinical stage through collaborating with academic institutes and cross-functional teams. At Ultragenyx Pharmaceutical Inc, California, he was the Translational Research Lead in several muscle and neurodevelopmental disease programs from early development of prodrug design and compound screening to clinical stage. As a graduate student in the laboratory of Dr. Elaine Fuchs, Dr. Chan identified the genetic basis of epidermolysis bullosa simplex, Weber-Cockayne type and held a faculty position at Geisinger Medical Center, Pennsylvania prior to joining industry. He is currently serving in the Scientific and Medical Advisory Board for CURE Congenital Muscular Dystrophy and Association for Creatine Deficiencies. Dr. Chan received his B.Sc. and Ph.D. degrees from the University of Chicago and completed his post-doctoral training under Dr. Louis Kunkel in Harvard Medical School.
Case Study by TWi Biotechnology: Use of Tofacitinib Citrate Gel in the Treatment of Atopic Dermatitis and Vitiligo 1:45 pm
• What is the role of tofacitinib, a JAK1/3 inhibitor, in pro-inflammatory cytokine pathways in immunological skin diseases? • Investigating the clinical development of topical tofacitinib using drug repurposing strategy • Reviewing tofacitinib efficacy results in recent clinical studies in atopic dermatitis and vitiligoRead more
day: Day Two